Declan Doogan, Director at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 76,898 shares at $44.11 ($3.5M) on 2019-02-22, disclosed to the SEC on 2019-02-26.
Open-market sale of $3.5M BHVN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.11 | 5,575 | $246K | 7.1% |
| 2 | $44.97 | 16,050 | $722K | 20.9% |
| 3 | $45.25 | 20,334 | $920K | 26.6% |
| 4 | $45.49 | 13,943 | $634K | 18.4% |
| 5 | $45.74 | 100 | $5K | 0.1% |
| 6 | $44.31 | 20,796 |
| $921K |
| 26.7% |
| 7 | $44.81 | 100 | $4K | 0.1% |
| Total | $44.90 avg | 76,898 | $3.5M | 100% |
| Filing → |
| BHVN | SELL | 2022-02-11 | $5.0M | — | Filing → |
| BHVN | SELL | 2021-12-01 | $5.5M | — | Filing → |
| BHVN | SELL | 2021-11-17 | $8.8M | — | Filing → |